Company: NDRA
Filing Date: 2025-10-30
Form Type: 424B5
Source: 0001213900-25-103705
Chunk: 70

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-10-30
Form: 424B5
Chunk 70
---
 join with them, they might not obtain the percentage necessary to request
the meeting. Therefore, stockholders holding less than 20% of the issued and outstanding common stock, without the assistance of management,
may be unable to propose a vote on any transaction that would delay, defer or prevent a change of control, even if the transaction were
in the best interests of our stockholders.

<div align='center'>22

PLAN OF DISTRIBUTION</div>

We may sell the securities offered by this prospectus
to one or more underwriters or dealers for public offering, through agents, directly to purchasers or through a combination of any such
methods of sale. The name of any such underwriters, dealers or agents involved in the offer and sale of the securities, the amounts underwritten
and the nature of its obligation to take the securities will be specified in the applicable prospectus supplement. We have reserved the
right to sell the securities directly to investors on our own behalf in those jurisdictions where we are authorized to do so. The sale
of the securities may be effected in transactions (a) on any national or international securities exchange or quotation service on which
the securities may be listed or quoted at the time of sale, (b) in the over-the-counter market, (c) in transactions otherwise than on
such exchanges or in the over-the-counter market or (d) through the writing of options.

We and our agents and underwriters may offer and
sell the securities at a fixed price or prices that may be changed, at market prices prevailing at the time of sale, at prices related
to such prevailing market prices or at negotiated prices. The securities may be offered on an exchange, which will be disclosed in the
applicable prospectus supplement. We may, from time to time, authorize dealers, acting as our agents, to offer and sell the securities
upon such terms and conditions as set forth in the applicable prospectus supplement. We may also sell the securities offered by any applicable
prospectus supplement in “at-the-market offerings” within the meaning of Rule 415 of the Securities Act, to or through a market
maker or into an existing trading market, on an exchange or otherwise.

If we use underwriters to sell securities, we
will enter into an underwriting agreement with them at the time of the sale to them. In connection with the sale of the securities, underwriters
may receive compensation from us in the form of underwriting discounts or commissions and may also receive commissions from purchasers
of